(Q34349641)

1 August 2017

title

Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis (English)

1 reference

1 August 2017

1 reference

1 reference

Marc Valentí

2

0 references

Eduard Vieta

object named as

Eduard Vieta

series ordinal

1

0 references

publication date

1 July 2013

1 reference

1 August 2017

1 reference

1 August 2017

volume

27

1 reference

1 August 2017

issue

7

1 reference

1 August 2017

page(s)

515-529

1 reference

The prevalence, clinical relevance, and public health significance of subthreshold depressions

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Subsyndromal depressive symptoms in patients with bipolar and unipolar disorder during clinical remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

The epidemiology of DSM-III-R bipolar I disorder in a general population survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Suicidal behaviour in bipolar disorder: risk and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Quality of life in bipolar disorder patients: a comparison with a general population sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Functional impairment and disability across mood states in bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Neurocognitive and symptomatic predictors of functional outcome in bipolar disorders: a prospective 1 year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

A 15-year prospective follow-up of bipolar affective disorders: comparisons with unipolar nonpsychotic depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Medicating mood with maintenance in mind: bipolar depression pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Bipolar depression: management options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Patterns of Psychotropic Drug Prescription for U.S. Patients With Diagnoses of Bipolar Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Case for caution, case for action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

New treatment guidelines for acute bipolar depression: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Is bipolar disorder still underdiagnosed? Are antidepressants overutilized?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Antidepressants for bipolar depression: a systematic review of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Efficacy and safety of fluoxetine in treating bipolar II major depressive episode.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Effectiveness of adjunctive antidepressant treatment for bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Mania associated with antidepressant treatment: comprehensive meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Risk factors for antidepressant-related switch to mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Bipolar mixed episodes and antidepressants: a cohort study of bipolar I disorder patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Lithium Response in Unipolar Versus Bipolar Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

The place of anticonvulsant therapy in bipolar illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

The Ham D(6) is more homogenous and as sensitive as the Ham D(17).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Pramipexole in treatment-resistant depression: a 16-week naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Pramipexole for bipolar II depression: a placebo-controlled proof of concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Modafinil for remitted bipolar depression with hypersomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Approved and investigational uses of modafinil : an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Inositol as an add-on treatment for bipolar depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Inositol augmentation of lithium or valproate for bipolar depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

The promise of N-acetylcysteine in neuropsychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Familial transmission of suicidal ideation and suicide attempts: evidence from a general population sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Early findings from a pharmacokinetically designed double-blind and placebo-controlled study of lithium for adolescents comorbid with bipolar and substance dependency disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Maintenance efficacy of divalproex in the prevention of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Inter-episodic morbidity and drop-out under carbamazepine and lithium in the maintenance treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Lamotrigine: a review of its use in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Maintenance therapy for bipolar disorder: current and future management options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Oxcarbazepine in the treatment of bipolar and schizoaffective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Atypical antipsychotics: newer options for mania and maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Clinical and therapeutic implications of predominant polarity in bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Risperidone plus lithium versus risperidone plus valproate in acute and continuation treatment of mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Antidepressants in bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Predominant polarity in bipolar disorder: Diagnostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0073-Y

Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes.

21 January 2018

1 reference

12 December 2020

Use of valpromide in psychiatric therapeutics

1 reference

12 December 2020

Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies

1 reference

12 December 2020

Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex

1 reference

12 December 2020

[Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder]

1 reference

12 December 2020

Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis

1 reference

12 December 2020

A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness

1 reference

12 December 2020

Carbamazepine compared with lithium in the treatment of mania

1 reference

12 December 2020

Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers

1 reference

12 December 2020

Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).

1 reference

12 December 2020

Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder

1 reference

12 December 2020

Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder.

1 reference

12 December 2020

International Consensus Group on the evidence-based pharmacologic treatment of bipolar I and II depression

1 reference

12 December 2020

Course of the Manic-Depressive Cycle and Changes Caused by Treatments

1 reference

12 December 2020

Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo

1 reference

12 December 2020

Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression.

1 reference

12 December 2020

Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.

1 reference

12 December 2020

Antidepressant-induced mania and cycle acceleration: a controversy revisited

1 reference

12 December 2020

The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients

1 reference

12 December 2020

Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression

1 reference

12 December 2020

Who responds to prophylactic lithium?

1 reference

12 December 2020

Lithium for maintenance treatment of mood disorders

1 reference

12 December 2020

The comparative efficacy of carbamazepine low and high serum level and lithium carbonate in the prophylaxis of affective disorders

1 reference

12 December 2020

Carbamazepine vs lithium in the treatment and prophylaxis of mania

1 reference

12 December 2020

Lithium versus carbamazepine in the maintenance treatment of bipolar disorders--a randomised study

1 reference

12 December 2020

A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.

1 reference

12 December 2020

Subsyndromal depression is associated with functional impairment in patients with bipolar disorder

1 reference

12 December 2020

Chronic neuroleptic use in manic-depressive illness

1 reference

12 December 2020

The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder

1 reference

12 December 2020

Clinical implications of predominant polarity and the polarity index in bipolar disorder: a naturalistic study

1 reference

12 December 2020

Modafinil augmentation of antidepressant treatment in depression.

1 reference

12 December 2020

The effect of carbamazepine and lithium on remission from affective illness

1 reference

12 December 2020

Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania

1 reference

12 December 2020

The package of care for patients with bipolar depression

1 reference

12 December 2020

Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders

1 reference

12 December 2020

Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials.

1 reference

12 December 2020

A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder

1 reference

12 December 2020

Olanzapine alone or in combination for acute mania

1 reference

12 December 2020

Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium

1 reference

12 December 2020

A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers.

1 reference

12 December 2020

Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study.

1 reference

12 December 2020

Pramipexole in refractory bipolar depression

1 reference

12 December 2020

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.

1 reference

12 December 2020

Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression

1 reference

12 December 2020

Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample

1 reference

12 December 2020

Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder

1 reference

12 December 2020

Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: fact or overinterpretation?

1 reference

12 December 2020

Diagnosing bipolar disorder: how can we do it better?

1 reference

12 December 2020

Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial

1 reference

12 December 2020

Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder

1 reference

12 December 2020

10.1007/S40263-013-0073-Y

Identifiers

DOI

1 reference

1 August 2017

1 reference